• Marie Moonen, Cécile Oury, and Patrizio Lancellotti.
• GIGA Cardiovascular Sciences, Departments of Cardiology, Cardio-Oncology Clinic, CHU Sart Tilman, University of Liège Hospital, 4000, Liège, Belgium.
• Curr Oncol Rep. 2017 Aug 8; 19 (10): 63.

AbstractContemporary cancer management has increased the overall number of cancer survivors, but cardiotoxicity remains a subject of concern, which is a major cause of noncancer mortality among survivors. Among the potential cardiovascular complications, left ventricular (LV) systolic dysfunction is a poor prognostic factor. The importance of its early detection is based on the principle that the likelihood of response to heart failure (HF) treatment is temporally related to the initiation of HF treatment. For these reasons, cardiac monitoring is commonly applied in general practice, based on serial measurements of LV ejection fraction (LVEF); transthoracic echocardiography (TTE) is generally used. However, the LVEF, as a diagnostic and predictive parameter, has significant limitations, which calls for more effective multimodality imaging strategies. This approach requires further study, but there is increasing available data in the literature, encouraging the combination of multimodality imaging parameters and techniques for early cancer therapeutic-related cardiac dysfunction (CTRCD) detection.

22 keywords...

hide…